 Leukemia
"Leukemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Descriptor ID |
D007938
|
| MeSH Number(s) |
C04.557.337
|
| Concept/Terms |
Leukemia- Leukemia
- Leukemias
- Leucocythaemia
- Leucocythaemias
- Leucocythemia
- Leucocythemias
|
Below are MeSH descriptors whose meaning is more general than "Leukemia".
Below are MeSH descriptors whose meaning is more specific than "Leukemia".
This graph shows the total number of publications written about "Leukemia" by people in this website by year, and whether "Leukemia" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1999 | 0 | 2 | 2 | | 2000 | 1 | 0 | 1 | | 2001 | 1 | 2 | 3 | | 2003 | 2 | 1 | 3 | | 2004 | 4 | 1 | 5 | | 2005 | 5 | 0 | 5 | | 2006 | 3 | 0 | 3 | | 2007 | 4 | 2 | 6 | | 2008 | 4 | 2 | 6 | | 2009 | 5 | 1 | 6 | | 2010 | 5 | 2 | 7 | | 2011 | 3 | 1 | 4 | | 2012 | 3 | 3 | 6 | | 2013 | 1 | 2 | 3 | | 2014 | 4 | 1 | 5 | | 2015 | 5 | 2 | 7 | | 2016 | 8 | 3 | 11 | | 2017 | 7 | 1 | 8 | | 2018 | 5 | 2 | 7 | | 2019 | 7 | 0 | 7 | | 2020 | 5 | 1 | 6 | | 2021 | 5 | 1 | 6 | | 2022 | 3 | 0 | 3 | | 2023 | 7 | 0 | 7 | | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Leukemia" by people in Profiles.
-
Stinchcombe TE, Wang X, Damman B, Mentlick J, Landreneau R, Wigle D, Jones DR, Conti M, Ashrafi AS, Liberman M, de Perrot M, Mitchell JD, Keenan R, Bauer T, Miller D, Altorki N. Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer. J Clin Oncol. 2024 Apr 01; 42(10):1110-1113.
-
Pollyea DA. Progress and challenges in the acute leukemia field. Best Pract Res Clin Haematol. 2023 12; 36(4):101524.
-
Fierro-Pineda JC, Tsai HL, Blackford A, Cluster A, Caywood E, Dalal J, Davis J, Egeler M, Huo J, Hudspeth M, Keating A, Kelly SS, Krueger J, Lee D, Lehmann L, Madden L, Oshrine B, Pulsipher MA, Fry T, Symons HJ. Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias. Blood Adv. 2023 09 26; 7(18):5639-5648.
-
Pillsbury CE, Dougan J, Rabe JL, Fonseca JA, Zhou C, Evans AN, Abukharma H, Ichoku O, Gonzalez-Flamenco G, Park SI, Aljudi A, DeRyckere D, Castellino SM, Rafiq S, Langermann S, Liu LN, Henry CJ, Porter CC. Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. Cancer Res Commun. 2023 07; 3(7):1248-1259.
-
Kaskovich S, Wyatt KD, Oliwa T, Graglia L, Furner B, Lee J, Mayampurath A, Volchenboum SL. Automated Matching of Patients to Clinical Trials: A Patient-Centric Natural Language Processing Approach for Pediatric Leukemia. JCO Clin Cancer Inform. 2023 07; 7:e2300009.
-
Cruz Cruz J, Allison KC, Page LS, Jenkins AJ, Wang X, Earp HS, Frye SV, Graham DK, Verneris MR, Lee-Sherick AB. Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment. Front Immunol. 2023; 14:1146721.
-
Patterson MT, Khan SM, Nunes NS, Fletcher RE, Bian J, Hadjis AD, Eckhaus MA, Mendu SK, de Paula Pohl A, Venzon DJ, Choo-Wosoba H, Ishii K, Qin H, Fry TJ, Cam M, Kanakry CG. Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects. Blood. 2023 02 09; 141(6):659-672.
-
Becht DC, Klein BJ, Kanai A, Jang SM, Cox KL, Zhou BR, Phanor SK, Zhang Y, Chen RW, Ebmeier CC, Lachance C, Galloy M, Fradet-Turcotte A, Bulyk ML, Bai Y, Poirier MG, C?t? J, Yokoyama A, Kutateladze TG. MORF and MOZ acetyltransferases target unmethylated CpG islands through the winged helix domain. Nat Commun. 2023 02 08; 14(1):697.
-
Liu L, Ma C, Zhang Z, Witkowski MT, Aifantis I, Ghassemi S, Chen W. Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse. J Immunother Cancer. 2022 12; 10(12).
-
Pietras EM, DeGregori J. Dangerous Liaisons between Tet2 Mutation, Inflammatory Monocytes, and Leukemogenesis. Cancer Discov. 2022 10 05; 12(10):2234-2236.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|